Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation
VANCOUVER, BC / ACCESSWIRE / October 30, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has signed on to support ground-breaking research with the MIND Foundation on a study on depression and psilocybin.
Havn Life is donating $20,000 to support this research, which will be the first psilocybin depression study in Germany since the 1970s.
"Like us, the MIND Foundation is focused on contributing to education and to the normalization of psychedelics," said Tim Moore, Havn Life CEO. "This psilocybin study in Europe will add to the global body of research, which is an essential part of moving this industry forward and developing a new generation of medicine. The Havn Life team intends to continue to identify research that's being conducted around the world, the Company believes it's paramount to support research as the industry evolves. "
The MIND Foundation is a non-profit in Berlin that promotes psychedelic research and educates professionals and the public about psychedelic treatments, integration, evidence-based harm reduction, and human development. Their work builds on the neurobiological and psychological potential of psychedelics to improve mental health and well-being in a clinical setting.
The planned psilocybin depression study has been initiated and is being led by principal investigator Prof. Dr. Gerhard Gründer at the Central Institute of Mental Health Mannheim, where he serves as head of the Molecular Neuroimaging Department. The study aims to investigate the safety and efficacy of psilocybin administered under supportive conditions in a controlled, randomized, double-blind design.
Prof. Dr. Gründer is currently the only scientist in Germany that is planning clinical research with psychedelics. He is a leading expert in his field, having conducted 30 years of psychiatric research on mental health disorders and addiction.
"Such a study can pave the way for future phase III studies and regulatory approval of this drug for standard treatment." said Prof. Dr. Gründer.
For the study, Prof. Dr. Gründer is working together with groups from the Charité Universitätsmedizin Berlin, Central Institute of Mental Health Mannheim, and the MIND Foundation, which has a team of over 20 scientists from around the world on its advisory board.
The study is expected to be approved within the next month by the ethics committee and the Federal Institute for Drugs and Medical Devices in Germany.
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
SOURCE: Havn Life Sciences Inc.
View source version on accesswire.com: